Taysha Gene Therapies, Inc. $TSHA Shares Acquired by SG Americas Securities LLC

Posted by George Bondi on Jun 28th, 2026

SG Americas Securities LLC lifted its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Free Report) by 178.5% during the 1st quarter, HoldingsChannel reports. The fund owned 2,176,742 shares of the company’s stock after purchasing an additional 1,395,268 shares during the period. SG Americas Securities LLC’s holdings in Taysha Gene Therapies were worth $9,730,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of the business. Marex Group plc purchased a new position in shares of Taysha Gene Therapies in the 2nd quarter valued at about $29,000. E Fund Management Co. Ltd. purchased a new position in Taysha Gene Therapies during the second quarter worth approximately $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Taysha Gene Therapies in the third quarter valued at approximately $40,000. Tower Research Capital LLC TRC grew its holdings in Taysha Gene Therapies by 156.5% in the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its position in shares of Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after buying an additional 4,607 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the transaction, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Price Performance

NASDAQ:TSHA opened at $6.34 on Friday. The stock has a 50 day moving average of $6.11 and a two-hundred day moving average of $5.29. Taysha Gene Therapies, Inc. has a 12 month low of $2.25 and a 12 month high of $7.30. The firm has a market cap of $1.82 billion, a P/E ratio of -16.68 and a beta of 1.19. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, analysts expect that Taysha Gene Therapies, Inc. will post -0.5 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Canaccord Genuity Group upped their target price on Taysha Gene Therapies from $14.00 to $17.00 and gave the stock a “buy” rating in a research note on Monday, April 6th. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Monday, June 22nd. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a report on Tuesday. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, March 19th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $12.38.

View Our Latest Analysis on Taysha Gene Therapies

Taysha Gene Therapies Company Profile

(Free Report)

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.